Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Anti-obesity medication is emerging as the latest pharma megatrend. However, the increasing demand for these semaglutide ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

While this class of drugs becomes ever more prevalent, and the wide-ranging positive health outcomes become better known, ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Now, green tea has followed the inevitable trajectory of any weight loss trick: It’s getting big on TikTok. Viral videos ...

Tolerability issues for CT-388 and CT-996 may impact Roche Holdings AG, but strong pipeline prospects remain. Discover why ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...